You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Advanced Hit Detection Systems
SBC: FREENT TECHNOLOGIES, INC. Topic: MDA13015FreEnt Technologies, Inc. (FreEnt) and Johns Hopkins Universitys Applied Physics Laboratory (APL) are proposing a multiple-hit detection sensor called the Optical Lethality Measurement System (OLMS). This system is based on the Planar Optical Penetration Sensor (POPS) technology (originally developed and patented by APL) and prior art associated with the Blast Initiation Detector (BID). The BID is ...
STTR Phase II 2017 Department of DefenseMissile Defense Agency -
AML MutationCounter a tool to detect residual and recurrent leukemia
SBC: Asystbio Laboratories, LLC Topic: 102Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
An Advanced Biosensor for Molecular Interaction Studies.
SBC: MOLECULAR SENSING, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Molecular interactions form the foundation of biology and chemistry. They are central to life itself and determine catalytic activity, cellular function, and therapeutic efficacy. The vast majority of diagnostic procedures depend on some type of specific molecular interaction. Therefore, the ability to perform pure liquid-phase molecular binding analysis at hi ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
A Novel Hernia Mesh to Improve Anchor Point Fixation and Prevent Hernia Formation
SBC: Deep Blue Medical Advances, Inc. Topic: 300Abstract Two million laparotomies are performed annually in the U S with ventral hernia being a frequent complication in of patients The average cost patient for each hernia operation in the U S in was $ which amounts to $ billion annually The ten year ventral hernia recurrence rate is There are $ B in hernia meshes sold annually in the United States With ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Randomized Blinded Placebo Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell LMSC Therapy for Treating The Metabolic Syndrome
SBC: Longeveron LLC Topic: NIAThe metabolic syndrome MetS is a cluster of factors that increases the risks for cardiovascular disease type diabetes mellitus and mortality and currently affects andgt of US adults MetS is associated with endothelial dysfunction decreased circulating endothelial progenitor cells EPCs and a pro inflammatory state We have made the exciting discovery that therapy with allogeneic me ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Artificial neural networks for high performance fully automated particle tracking analysis even at low signal to noise regimes
SBC: AI Tracking Solutions LLC Topic: 400Abstract Particle tracking PT is a powerful biophysical tool for elucidating molecular interactions transport phenomena and rheological properties in complex biological environments Unfortunately PT remains a niche tool in life and physical sciences with a limited user base in large part due to significant time and technical constraints in extracting accurate time variant positional data fr ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells
SBC: CELL MICROSYSTEMS INC Topic: NIAIDProject SummaryAdoptive cell therapyACTis an emerging immunotherapy which shows significant promise in treating both leukemia and solid tumorsas well as certain infectious diseasesACT comprises the isolation and ex vivo expansion of cytotoxic T lymphocytesCTLsrecognizing epitopes of a mutated or aberrantly expressed protein present almost exclusively on the surface of a patient s tumor cellsTo mee ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Controlling mechanical signal transduction to treat osteoarthritis
SBC: Cytex Therapeutics, Inc. Topic: NIADESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Creation of animal models of mitochondrial DNA disease for translational research applications
SBC: ENZERNA BIOSCIENCES LLC Topic: 400Mitochondria are the principal generators of cellular ATP by oxidative phosphorylation which links electron transport via Complexes I through IV to production of ATP via ATP synthase Over pathogenic human mitochondrial DNA mtDNA mutations associated with diseases ranging from cardiomyopathy to juvenile blindness have been identified Collectively millions are affected by mtDNA disease fo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a new therapeutic agent for retinal ciliopathies
SBC: Rescindo Therapeutics Inc Topic: NThe ciliopathies are a group of andgt overlapping clinical disorders caused by defects in the primary cilium and its anchoring structure the basal body Although individually rare this group contributes significantly to the population genetic disease burden with some estimates placing their combined incidence to as much as Importantly although some ciliopathies are lethal most pat ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health